3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Conditions
Melanoma
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, T-Cell
1
Head and Neck Carcinoma
1
Glioblastoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Interventions
Etoposide
18
Carboplatin
18
pembrolizumab
15
Nivolumab
11
Cisplatin
11
atezolizumab
8
Topotecan
8
Irinotecan
7
Temozolomide
6
Paclitaxel
5
PM 01183
5
Ipilimumab
5
Gemcitabine
5
olaparib
4
Radiotherapy
4
Docetaxel
4
surufatinib
3
durvalumab
3
carfilzomib
3
Bevacizumab
3
veliparib
2
trilaciclib
2
sacituzumab govitecan
2
rovalpituzumab tesirine
2
obatoclax
2
niraparib
2
navitoclax
2
lorvotuzumab mertansine
2
lenvatinib
2
fluzoparib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Small Cell Lung Carcinoma
×
Solutions
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled